Millennium Management
MREO

Millennium Management’s Mereo BioPharma MREO Stock Holding History

Millennium Management’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.17M Buy
3,559,103
+3,475,457
+4,155% +$1.49M ﹤0.01% 4276
2025
Q4 		$34.9K Sell
83,646
-253,857
-75% -$483K ﹤0.01% 5776
2025
Q3 		$695K Sell
337,503
-258,170
-43% -$476K ﹤0.01% 4874
2025
Q2 		$1.61M Buy
595,673
+201,242
+51% +$486K ﹤0.01% 4058
2025
Q1 		$887K Sell
394,431
-3,571,001
-90% -$10.1M ﹤0.01% 4442
2024
Q4 		$13.9M Sell
3,965,432
-1,429,259
-26% -$5.62M 0.01% 1859
2024
Q3 		$22.2M Buy
5,394,691
+2,192,986
+68% +$9.07M 0.01% 1465
2024
Q2 		$11.5M Buy
3,201,705
+1,022,570
+47% +$3.31M 0.01% 1963
2024
Q1 		$7.19M Buy
2,179,135
+768,818
+55% +$2.6M ﹤0.01% 2502
2023
Q4 		$3.26M Buy
1,410,317
+166,732
+13% +$319K ﹤0.01% 3170
2023
Q3 		$1.6M Buy
1,243,585
+288,514
+30% +$383K ﹤0.01% 3768
2023
Q2 		$1.26M Sell
955,071
-1,550,559
-62% -$1.8M ﹤0.01% 3852
2023
Q1 		$1.77M Buy
2,505,630
+1,194,281
+91% +$1.07M ﹤0.01% 3555
2022
Q4 		$984K Buy
1,311,349
+57,738
+5% +$47.4K ﹤0.01% 4182
2022
Q3 		$1.08M Buy
1,253,611
+551,715
+79% +$675K ﹤0.01% 4275
2022
Q2 		$786K Sell
701,896
-216,162
-24% -$167K ﹤0.01% 4589
2022
Q1 		$1.03M Sell
918,058
-32,976
-3% -$42.6K ﹤0.01% 4484
2021
Q4 		$1.52M Sell
951,034
-483,510
-34% -$967K ﹤0.01% 4022
2021
Q3 		$3.47M Sell
1,434,544
-229,406
-14% -$607K ﹤0.01% 3301
2021
Q2 		$5.28M Sell
1,663,950
-925,417
-36% -$3.1M ﹤0.01% 2686
2021
Q1 		$8.73M Buy
2,589,367
+2,428,187
+1,507% +$8.58M 0.01% 1934
2020
Q4 		$577K Buy
+161,180
New +$404K ﹤0.01% 4088

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management's MREO Position: Q1 2026 in Review

Millennium Management increased its Mereo BioPharma (MREO) stake by 4,155% in Q1 2026, buying an estimated $1.49M and bringing the position to 3,559,103 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #4276.

Millennium Management first reported a position in MREO in Q4 2020 and has held it in 22 quarters since. The position peaked at $22.2M in Q3 2024. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

  • Millennium Management held 3,559,103 shares of Mereo BioPharma worth $1.17M as of Q1 2026.
  • Millennium Management bought 3,475,457 Mereo BioPharma shares in Q1 2026, an estimated $1.49M.
  • Mereo BioPharma made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #4276 holding.
  • Millennium Management first reported a position in Mereo BioPharma in Q4 2020 and has held it in 22 quarters since.
  • Millennium Management's Mereo BioPharma position peaked at $22.2M in Q3 2024.
  • 63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.